Sense Neuro Diagnostics receives $2.43 Million from US Military to advance technology to diagnose and monitor traumatic brain injury (TBI) in a field environment

Sense Neuro Diagnostics receives $2.43 Million from US Military to advance technology to diagnose and monitor traumatic brain injury (TBI) in a field environment




Sense Neuro Diagnostics receives $2.43 Million from US Military to advance technology to diagnose and monitor traumatic brain injury (TBI) in a field environment

  • TBI is a signature wound of recent wars
  • Award will accelerate development of Sense’s rapid, non-invasive brain scanners through clinical testing, to enable objective method of detecting and continuously monitoring TBI through transport to field hospital

CINCINNATI–(BUSINESS WIRE)–#TBISense Neuro Diagnostics, a medical technology company focused on improving outcomes for stroke and brain injury patients, today announced its selection by the U.S. Army Medical Research and Development Command (USAMRDC) Combat Casualty Care Research Program to receive $2.43 million from the U.S. Department of Defense to advance technology to diagnose and monitor traumatic brain injury (TBI) in a field environment. The award was issued through Medical Technology Enterprise Consortium (MTEC), a biomedical technology consortium working to advance innovative medical solutions to keep military personnel healthy and fully operational.

“We believe Sense Neuro Diagnostics is well positioned to deliver on USAMRDC’s goals of improving outcomes for service members who suffer traumatic brain injury,” said Geoff Klass, CEO of Sense Neuro Diagnostics. “With rapid detection and continuous monitoring, our technology will enable proper triage and treatment when it matters most.”

TBI is a signature wound of recent wars, with roughly 420,000 documented incidents of service members sustaining at least one TBI in the last two decades. Proper diagnosis and treatment are critical in the 1-3 days following brain injury, but battlefield and far-forward operational conditions make evacuation difficult, potentially delaying diagnosis and vital care. There is currently no objective tool for diagnosing and monitoring TBI and brain hemorrhage in a field environment, with medical personnel instead relying on a patient questionnaire and the Glasgow Coma Scale to diagnose and stratify the severity of TBI.

Sense is developing rapid, non-invasive brain scanners that use low-power tailored radio frequency (RF) pulse to detect TBI in seconds and, through continuous monitoring, indications of expanding brain hemorrhage. The scanners are small, flexible, and portable, designed to fit on a patient’s head like a cap. The technology was invented by Sense’s medical co-founders who are specialists in emergency medicine, neurology and neurocritical care.

The MTEC award will fund the completion of product development and clinical testing over the next 18 months.

“It’s an honor to develop technology for the USAMRDC that has potential to improve outcomes for the men and women who suffer traumatic injury in service to our country,” said Daniel Kincaid, Chief Operating Officer of Sense Neuro Diagnostics.

About Sense Neuro Diagnostics

Sense Neuro Diagnostics is a medical technology company focused on improving outcomes for stroke and brain injury patients through technology innovations that enable faster detection and more effective triage. Sense is developing non-invasive technology to enable continuous, real-time brain injury monitoring as well as rapid detection of traumatic brain injury and important stroke subtypes—ischemic stroke with large vessel occlusion, ischemic stroke without large vessel occlusion, and intracerebral hemorrhage. Learn about the ongoing pivotal trial for continuous monitoring of intracranial hemorrhage, and successful first-in-human pilot study of triage technology to determine stroke subtype at https://senseneuro.com or find Sense Neuro Diagnostics on LinkedIn or Twitter @SenseDx.

About U.S. Army Medical Research and Development Command

The U.S. Army Medical Research and Development Command is the Army’s medical materiel developer, with responsibility for medical research, development, and acquisition. USAMRDC produces medical solutions for the battlefield with a focus on various areas of biomedical research, including military infectious diseases, combat casualty care, military operational medicine, medical chemical and biological defense. https://mrdc.amedd.army.mil/

About Neurotrauma at Combat Casualty Care Research Program

The Neurotrauma and Traumatic Brain Injury Portfolio is a requirements-based program that seeks to improve the far-forward capabilities of military diagnostic and treatment for the spectrum of TBI severities, with emphasis on moderate and severe TBI and polytrauma under Multi-Domain Operations in prolonged field care scenarios. https://ccc.amedd.army.mil/Portfolios/Pages/NTBI.aspx

About MTEC

MTEC is a biomedical technology consortium collaborating with multiple government agencies under a 10-year renewable Other Transactional Agreement with the U.S. Army Medical Research and Development Command. To find out more about MTEC, visit mtec-sc.org.

Contacts

Peg Rusconi

prusconi@senseneuro.com
+1.617.910.6217